Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wasn’t the site up and running the last couple of months already?
Then again, Rett gets misdiagnosed all the time too!!!!, RIGHT?
And Parkinson’s
And depression
And....
AND.....
I seem to have forgotten about MS.
Ahh sugar. Looks like I’m gonna need some A-273 once approved to help with MY memory.
I do believe the pps was above $3, which then means they could have used the agreement they already had in place.
Last I remember, ain’t the IP protected until 2031?
How is that soon?
Second-generation drugs are harder to bring to market, because they are harder to study, Gottlieb said.
“Typically, the subsequent drugs will have to be studied on top of the available therapy and you’ll have to show improved efficacy with combination therapy as opposed to just monotherapy,” Gottlieb said. “It’s hard to run head-to-head comparative studies when already effective therapy is available. People don’t want to forego an effective treatment especially, when you’re dealing with a child with degenerate disease.”
https://cancerletter.com/articles/20180727_4/
Seems like mission accomplished for BIIB. Their goal was:
Take interest away from AVXL and stay on BIIB. Why else would they want to change presentations to AFTER Anavex.
Make bio markers a side topic and keep amyloid on the front burner. Even though the following shows that even analysts are doubting the Amyloid theory
https://www.statnews.com/2018/07/26/biogen-lost-7-billion-overnight-despite-positive-alzheimers-data/
Even if it costs them many Billions in valuation, that’s more shares needing to be sold by Anavex to raise money when it comes time. They have the money and influence to outlast Anavex financially. Curve ball being while we wait for approval for trial start in the U.S. we will start them in the EU and Australia in the mean time.
Cant wait for both trials to start and watch the haves be separated from the have not.
Then there’s A-371 batting cleanup!!!!
Someone’s excited to listen to the presentation
https://mobile.twitter.com/alzgirllori
HH could be the only one raising his hand and I doubt BIIB would have the “fruits” to allow him to ask a question.
Lol dumped on low volume?
The bigger question is what happened to MS on the pipeline path and anything mentioning a-273 being used in ms?
Nice Bio,
The next months/ year will be very intriguing as BIIB, with their grand illusion, is up against a very sharp navigator thats smoothly guiding us through some infested waters.
Lol, for small bios that would pr the exact same things would be called a pr machine, sp pumping even.
What say you about one last attack before AAIC.
Seems different than previous conferences Anavex has attended.
Being realistic and expecting nothing spectacular, just more positive data confirming a p3 is needed.
If something spectacular does get released, awesome.
If not, onward we march into p2 and p2/3 trials.
Translated into English:
Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability and efficacy of ANAVEX2-73 in relation to cognitive deterioration in patients with Parkinson's disease and dementia.
Cognitive impairment in Parkinson's disease with dementia
Not started
Authorization date: 07/03/2018
Imagining that one day, if everything falls into place, Avxl will be more than an ARYC bet from 3 years ago. Still holding strong at a cool 1100% in the green.
Could it be why Anavex went ahead and did even further IP protection as discovered on the board a few weeks ago?
But hey, that’s the risks one takes if they want that imaginary 10x LESS likely.
Never mind about a-273 trial and what it could mean for the older population, just take herpes medicine along with these possible side effects. Guess what though, it doesn’t guarantee you won’t get Alz, just reduce your chances.
Lol, BP solutions.
What do you think BIIB and their BAN product is? Nothing more than a game of poker against Anavex. Bluffing that they possibly might have something. Another amyloid, that needs to be taken by injection for 12.... wait 18 months to get any shred of improvement. Wait.... that’s using an all new test created by whom?
Yea, and Anavex and their a-273 is suspect.
Wouldn’t allowing non bio marker subjects in any part of the trial be asking for criticism?
I can hear the fud already, never mind how spectacular the results
You know how often misdiagnosis happens in Alz trials?
Seems as if it has to happen pretty often to get the results Anavex is seeing so far.
I’m curious if said participant started driving again. THAT trumps all others as it takes a lot of brain functioning to drive safely.
At least in Hawaii it does.
Nah, more like a-273 would be part of the daily multi vitamin pack
2018 Dementia Grants Program - Round 1 NOW CLOSED
The purpose of this Grant is to fund generously a single, high-quality, innovative and possibly paradigm-changing research project that could transform the landscape of dementia research
That so sounds like words the company used it presentations.
Said it won’t be chosen until Oct 2018.
https://www.dementia.org.au/research/grants
Old news, but since approved for the p2/3 trial, could it be......?
Me thinks a picture could be drawn and some still would act as if they don’t get it.
After all, how could a trial with 25 do more for Alz patients than the last 100-200 trials total.
So with Anavex moving time slots to right before BIIB, is that good or bad?
Curious to know everyone’s thoughts
And on goes the fluff.
I’m sure they have and still are trying to get Avxl on the cheap.
To think otherwise is foolish.
A-273 has done more positive for those 32 trial patients than whatever other ALZ trial BIIB has ran.
FACT
Actually, he was here during that run up in 2015.
Someone seems hurt about it.
Maybe it’s the surprise that a trial or two can start outside of the U.S.?
Lol, the things that are said to see what sticks.
I’m excitedly waiting to see the next angle that’ll try to be used.
Good ol printshop might work.
I remember reading posts at least a year or two ago talking about how big players buy once a trial starts the p3 and never before.
Would that still hold true today?
Nah, Missling is just setting the stage to explain how the trial will run at AAIC.
What the targets will be, and all that other stuff they’ve been working on the past few years.
Markets close @ 1pm anyway, right.
And to think Missling would settle for $20 a share is ludicrous. Anavex and it’s pipeline has the potential to run the tables across CNS diseases.
Sure we have a ways to go yet, and still...... we keep chugging along.
It shows that many simply don’t know about Anavex and the possibilities that it could deliver.
Only time will tell if they will succeed.
Interesting find and discussion today. Why strengthen IP if they have nothing?
Who’s hoodwinking whom?
Nice try to cover up that blunder.
Bottom line, words are words and once the trials start I’m sure another silly excuse will be made as to why Anavex is a bad investment.
For me, I’m waiting for the trials and partial read outs before I decide to either add more, or sell. Until then..... I have 40 years for my 401 AVXL shares to mature.
I already said many times this came up, I don’t buy it. Next
Wait a minute. The data is on the first 3 patients enrolled on a p1/2a study.
Anavex reported on initial 32 for p2a/b and got bashed for it.
Anyone care to explain
Found it. Source is none other than........
Thestreet
Written by......
AF
https://www.google.com/amp/s/www.thestreet.com/amp/story/14082476/1/for-these-small-cap-biotech-ceos-stock-promotion-not-drug-development-was-priority-no-1.html
Don’t take everything you read on here as true.
Just might end up like Cortana and file a lawsuit with that 100 shares